Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

13.64 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000 ↗
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address... 
Via Benzinga
News headline image
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. 
Via Talk Markets
News headline image
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
News headline image
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week ↗
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. 
Via Talk Markets
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
News headline image
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued ↗
Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The... 
Via Benzinga
News headline image
Why Is Clearmind (CMND) Stock Up 40% Today? ↗
The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing. 
Via InvestorPlace
News headline image
MindMed Announces Business Update and Anticipated Milestones for 2024
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From January 1, 2024 ↗
 
Via Benzinga
News headline image
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Up In December; Down YTD ↗
The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. 
Via Talk Markets
News headline image
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Declined 1.6% This Week ↗
Our Psychedelic Drug Stocks Index is now down 11.5% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, remains down 28.8% YTD. 
Via Talk Markets
Topics ETFs
News headline image
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed ↗
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no... 
Via Benzinga
News headline image
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
From Mind Medicine
Via Business Wire
News headline image
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
News headline image
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week ↗
The 5 constituents in our Psychedelic Drug Stocks Index jumped 30.2%, on average, in November and were up a further 2.8% last week. 
Via Talk Markets
News headline image
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
News headline image
November Recap: Psychedelic Drug Stocks Index Driven 30% Higher By Incannex ↗
The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November. 
Via Talk Markets
News headline image
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
Via Benzinga
Topics Cannabis
News headline image
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
GH Research Drags Down Psychedelic Drug Stocks Index By 7% ↗
The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. 
Via Talk Markets
News headline image
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? 
Via Benzinga
Topics Initial Public Offering
News headline image
Psychedelic Compound-Based R&D Stocks Not For The Faint Of Heart ↗
Our Psychedelic Drug Stocks Index continues to exhibit extreme volatility, declining 8% this week, jumping 22% the previous week and falling 6.5% the week before that. This week's decline is based on... 
Via Talk Markets
News headline image
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court 
Via Benzinga
Topics Economy
News headline image
Favorable Q3 Financial Reports Lift Largest Psychedelic Sector Stocks By 22% ↗
The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances last week along with any pertinent news affecting their performances. 
Via Talk Markets
News headline image
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved ↗
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has shared its financial outcomes for the third quarter ended September 30, 2023. In numbers: 
Via Benzinga
News headline image
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
From Mind Medicine
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.